Tepotinib (Tepmetko®). HTA ID: 22025

Assessment Status NCPE Assessment Process Complete
HTA ID 22025
Drug Tepotinib
Brand Tepmetko®
Indication For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Assessment Process
Rapid review commissioned 22/04/2022
Rapid review completed 30/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tepotinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 13/09/2022
Full submission received from Applicant 10/01/2023
Preliminary review sent to Applicant 23/05/2023
NCPE assessment re-commenced 22/06/2023
Factual accuracy sent to Applicant 18/10/2023
NCPE assessment re-commenced 03/11/2023
NCPE assessment completed 29/11/2023
NCPE assessment outcome The NCPE recommends that tepotinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.